Client services:(888)700-7110

Investor Overview

  1. Chart
  2. Quote
Stock price graph
+ 0.16
Day High:
Day Low:
4:00 PM ET on Feb 26, 2015

Delayed at least 20 minutes.
Provided by eSignal.

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit

View all »   RSSRecent Releases

Jan 15, 2015
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015

Dec 11, 2014
Response Genetics Secures New York State Department of Health Approval for the Company's ResponseDX(R) Testing Services